How Much Does Addyi (Flibanserin) Cost in District of Columbia in 2026?

Brand-Name Addyi Pricing in DC

The manufacturer list price set by Sprout Pharmaceuticals for Addyi is $880 per month for a 30-count supply of 100 mg tablets. DC retail pharmacies generally reflect this price for uninsured cash-pay customers. That figure has held steady since Sprout's last pricing adjustment, and no generic version of flibanserin has reached the US market as of May 2026.

Addyi received FDA approval in August 2015 as the first pharmacotherapy for acquired, generalized HSDD in premenopausal women. The approval followed three Phase III trials, including the BEGONIA trial (N=1,087), which demonstrated a statistically significant increase in satisfying sexual events (SSEs) of 0.8 per month over placebo (P<0.01). The drug acts on serotonin 5-HT1A and 5-HT2A receptors and on dopamine D4 receptors, a mechanism distinct from hormonal therapies.

Price alone does not capture total cost. Patients should factor in the mandatory REMS certification (prescriber and pharmacy enrollment), potential lab work, and follow-up visits when estimating their annual spending on Addyi in the District.

DC Medicaid Coverage for Flibanserin

District of Columbia Medicaid covers Addyi, but only with prior authorization (PA). The PA process requires the prescriber to document a clinical diagnosis of HSDD in a premenopausal woman, confirm that the condition is acquired and generalized rather than situational, and verify that reversible causes (medication side effects, relationship factors, other psychiatric conditions) have been assessed.

Processing times for DC Medicaid PA requests typically range from 24 to 72 hours. Denials can be appealed through the DC Department of Health Care Finance (DHCF) fair hearing process. Dr. Sheryl Kingsberg, a clinical psychologist who served on the FDA advisory committee for flibanserin, has noted: "Prior authorization creates a real barrier for women who have already overcome the stigma of seeking help for low desire. The extra step causes a significant percentage to abandon the prescription entirely."

Practical tips for a smoother PA process: ask your prescriber to include your Female Sexual Function Index (FSFI) score, document the duration of symptoms (the DC formulary committee generally expects six months or longer), and attach chart notes showing that alternative explanations were ruled out. Patients enrolled in DC Medicaid managed care organizations (MCOs) such as AmeriHealth Caritas or CareFirst Community Health Plan should call the MCO pharmacy line directly, as the PA pathway may differ slightly from fee-for-service Medicaid.

Private Insurance Coverage in the District

Commercial insurers in DC vary widely in their approach to Addyi. CareFirst BlueCross BlueShield, the dominant carrier in the District, places flibanserin on a specialty or non-preferred brand tier. Patients with CareFirst plans should expect a prior authorization requirement and, if approved, a co-pay that typically falls between $50 and $150 per month depending on the plan's tier structure.

Aetna, Cigna, and UnitedHealthcare plans sold on the DC Health Benefit Exchange (DC Health Link) also list Addyi but often require step therapy documentation or PA. The Endocrine Society's 2019 clinical practice guideline recommends pharmacotherapy for HSDD when psychological and relationship interventions have been insufficient, a standard that most insurers reference when adjudicating PA requests.

Self-insured employer plans (ERISA plans) follow their own formulary rules and are not bound by DC insurance mandates. Patients on ERISA plans who face a denial should request an external review, which is administered at the federal level. The denial rate for flibanserin PA requests across commercial plans nationally sits near 30%, according to pharmacy benefit manager data compiled by the American Association of Clinical Endocrinology.

A useful first step: call the number on the back of your insurance card, ask whether flibanserin carries a PA requirement, and request the specific clinical criteria. Having those criteria in hand before your prescriber submits the request saves time and reduces the chance of a preventable denial.

Compounded Flibanserin in DC

Compounded flibanserin is available through licensed 503A compounding pharmacies in the District of Columbia. These pharmacies prepare the medication pursuant to individual patient prescriptions, and the practice is legal under federal law (Section 503A of the Federal Food, Drug, and Cosmetic Act) and DC Board of Pharmacy regulations.

Monthly costs for compounded flibanserin at DC-area 503A pharmacies typically range from $30 to $90, a fraction of the $880 brand-name price. The compounded product is not FDA-approved, and it does not carry the same REMS restrictions as brand-name Addyi. That means the prescriber does not need REMS certification to write for the compounded version, and the pharmacy does not need REMS enrollment to dispense it.

There are trade-offs. Compounded products do not undergo FDA review for bioequivalence, so absorption profiles could differ from the branded tablet. The FDA's guidance on compounding makes clear that 503A pharmacies must compound in response to a valid prescription for an individually identified patient and may not produce large batches for general distribution (that would require 503B outsourcing facility registration). Patients should confirm that their pharmacy holds a current DC Board of Pharmacy compounding license and follows USP Chapter 795 standards for non-sterile compounding.

Some telehealth platforms that serve DC residents partner directly with 503A pharmacies, bundling the consultation fee and compounded medication into a single monthly subscription. These arrangements can bring the all-in cost below $100 per month.

Telehealth Access to Addyi in DC

Telehealth prescribing of Addyi is fully legal in the District of Columbia. DC's telehealth parity law (DC Code § 31-3861 et seq.) requires insurers to cover telehealth-delivered services at the same rate as in-person visits when the service is clinically appropriate. A synchronous video or audio visit with a licensed prescriber who holds a DC medical license (or a license recognized under an interstate compact) satisfies the prescribing requirements.

For brand-name Addyi, the prescriber must complete the REMS certification and counsel the patient on the alcohol interaction risk before writing the prescription. This counseling can be performed via telehealth. The REMS program requires pharmacies to be certified as well, so the patient's chosen pharmacy must be enrolled before dispensing.

Several national telehealth platforms now serve DC for HSDD treatment. Visit costs range from $30 to $99 for an initial consultation, with follow-up visits often priced lower. Patients who opt for compounded flibanserin through a telehealth platform can bypass the REMS requirement entirely, since the REMS applies only to the branded product.

Dr. Anita Clayton, professor of psychiatry at the University of Virginia and a principal investigator in multiple flibanserin trials, has stated: "Telehealth removes geography as a barrier. Women in areas with few sexual-medicine specialists can now access evidence-based treatment without a two-hour drive."

Discount Programs and Savings Strategies

The Sprout Pharmaceuticals savings card is the primary manufacturer-sponsored discount for Addyi. Commercially insured patients who present the card at a participating DC pharmacy may pay as little as $0 to $25 per month, depending on their plan's co-pay structure. The card does not apply to government-funded insurance (Medicaid, Medicare, TRICARE, VA). Patients can enroll at the Addyi website or request a card through their prescriber's office.

Beyond the savings card, several strategies can reduce costs for DC residents:

GoodRx and RxSaver coupons. These aggregator platforms negotiate discounted cash-pay rates with pharmacy benefit managers. Prices for brand-name Addyi with a coupon fluctuate but occasionally dip below $800 per month at specific DC pharmacies such as CVS, Walgreens, or Costco (Costco does not require a membership to use its pharmacy).

Patient assistance programs. Sprout Pharmaceuticals offers a patient assistance program (PAP) for uninsured or underinsured patients whose household income falls below 400% of the federal poverty level. The program provides Addyi at no cost to qualifying patients. Application requires proof of income, a valid prescription, and documentation of insurance status.

Compounding as a cost strategy. For patients whose primary concern is price, compounded flibanserin at $30 to $90 per month represents the largest potential savings. The clinical trade-off (no FDA-reviewed bioequivalence data) should be discussed with the prescriber.

Pill splitting. Addyi tablets are scored. However, the FDA-approved dose is 100 mg nightly, and no clinical trial data support a 50 mg dose for HSDD. Pill splitting is not recommended without prescriber guidance.

Clinical Efficacy: What DC Patients Should Know Before Paying

Given the cost, patients should understand what flibanserin does and does not deliver. Across three key trials, flibanserin 100 mg increased the mean number of SSEs by approximately 0.5 to 1.0 per month over placebo. The BEGONIA trial specifically reported a mean increase of 1.6 SSEs per month in the flibanserin group versus 0.8 in the placebo group at 24 weeks. Sexual desire, measured by the desire domain of the FSFI, also improved significantly (P<0.01) compared with placebo.

The most common side effects are dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%), based on pooled Phase III data. The REMS program exists because of the risk of severe hypotension and syncope when flibanserin is combined with alcohol. In a dedicated interaction study, 17% of subjects who took flibanserin with alcohol experienced hypotension or syncope requiring medical intervention compared with 0% taking placebo with alcohol.

Response typically takes eight weeks. The FDA label recommends discontinuing Addyi after eight weeks if the patient does not report improvement in sexual desire or associated distress. That two-month trial window means a DC patient paying $880 per month out-of-pocket would spend $1,760 before knowing whether the drug works for her. Using the savings card or compounded flibanserin reduces the financial risk of that trial period substantially.

Comparing Addyi to Other HSDD Options Available in DC

Addyi is not the only pharmacotherapy for HSDD. Vyleesi (bremelanotide), an on-demand subcutaneous injection approved in 2019, costs approximately $950 per month (eight auto-injectors) at DC retail pharmacies. Vyleesi does not carry an alcohol contraindication or a REMS program, but its injection route and side-effect profile (nausea in 40% of patients in the RECONNECT trial, N=1,247) limit its appeal for some women.

Off-label testosterone therapy, compounded as a topical cream or gel, is another option used by some DC clinicians. The International Society for the Study of Women's Sexual Health (ISSWSH) endorses transdermal testosterone at a dose of 300 mcg daily for postmenopausal women with HSDD, but no FDA-approved testosterone product exists for women. Compounded testosterone cream through a DC 503A pharmacy costs roughly $20 to $60 per month. Testosterone is only supported by evidence for postmenopausal HSDD; Addyi's indication is specifically premenopausal.

The choice between Addyi, Vyleesi, and off-label testosterone depends on menopausal status, tolerance for side effects, preference for daily versus on-demand dosing, and cost sensitivity. A DC prescriber specializing in sexual medicine can walk through the decision matrix during a telehealth or in-person visit.

How to Fill an Addyi Prescription in DC

Step one: confirm your prescriber is REMS-certified (for brand-name Addyi only). Step two: choose a REMS-enrolled pharmacy. Major chains in DC (CVS, Walgreens, Rite Aid) participate in the REMS program, but call ahead to verify enrollment and stock. Step three: if using insurance, ask your prescriber to submit the PA before sending the prescription to the pharmacy to avoid dispensing delays. Step four: pick up the medication and schedule a follow-up at eight weeks to assess response.

For compounded flibanserin, the process is simpler. Any DC-licensed prescriber can write the prescription. Any DC Board of Pharmacy-licensed 503A compounding pharmacy can fill it. No REMS enrollment is required on either side.

Patients who fill via mail-order pharmacy should verify that the pharmacy ships to DC and holds appropriate licensure. Some mail-order compounding pharmacies based outside DC hold non-resident pharmacy licenses issued by the DC Board of Pharmacy, which allows them to legally ship compounded flibanserin to District addresses.

The bedtime-only dosing instruction is non-negotiable. Flibanserin taken during waking hours significantly increases the risk of hypotension, dizziness, and syncope, per the FDA label. Set a consistent bedtime alarm as a reminder, and do not consume alcohol within two hours of the dose.